Recursion Pharmaceuticals (RXRX) Net Cash Flow (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Net Cash Flow came in at -$84.9 million in Q1 2026, up 13.97% YoY from -$74.5 million in Q1 2025, and down 200.26% on a QoQ basis from $84.7 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Net Cash Flow (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Net Cash Flow data on file, last reported at -$84.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 13.97% year-over-year to -$84.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.6 million (down 27.17% YoY) and the FY2025 annual result came in at $132.9 million, down 35.2% from the prior year.
- Net Cash Flow retreated to -$84.9 million in Q1 2026, from $84.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $222.8 million in Q1 2022 to a low of -$98.7 million in Q1 2025.
- A 5-year average of $21.1 million and a median of $780000.0 in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 2600.26% — and 2024, when it jumped 4068.66%.
- Tracing RXRX's Net Cash Flow over 5 years: stood at $94.5 million in 2022, then tumbled by 95.67% to $4.1 million in 2023, then jumped by 4068.66% to $170.7 million in 2024, then slumped by 50.38% to $84.7 million in 2025, then tumbled by 200.26% to -$84.9 million in 2026.
- The last three Net Cash Flow figures came in at -$84.9 million (Q1 2026), $84.7 million (Q4 2025), and $131.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -109.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -109.17 Mn |
| Jun 30, 2026 | -109.17 Mn |
| Mar 31, 2026 | -84.91 Mn |
| Mar 31, 2026 | -84.91 Mn |
| Dec 31, 2025 | 84.69 Mn |
| Dec 31, 2025 | 84.69 Mn |
| Sep 30, 2025 | 131.43 Mn |
| Sep 30, 2025 | 131.43 Mn |
| Jun 30, 2025 | 15.43 Mn |
| Jun 30, 2025 | 15.43 Mn |
| Mar 31, 2025 | -98.70 Mn |
| Mar 31, 2025 | -98.70 Mn |
| Dec 31, 2024 | 170.67 Mn |
| Dec 31, 2024 | 170.67 Mn |
| Sep 30, 2024 | -47.33 Mn |
| Sep 30, 2024 | -47.33 Mn |
| Jun 30, 2024 | 176.72 Mn |
| Jun 30, 2024 | 176.72 Mn |
| Mar 31, 2024 | -95.06 Mn |
| Mar 31, 2024 | -95.06 Mn |